24. March 2016

Zai Lab signs a supply agreement with Boehringer Ingelheim Biopharma

  • Boehringer Ingelheim will for the first time partner with a local company in Zhangjiang, providing process optimization and manufacturing services for Zai Lab’s new monoclonal antibody
  • The new monoclonal antibody will be used to treat autoimmune diseases
  • The pilot MAH/CMO project will foster R&D and market launch of innovative bio-medicines in China


Shanghai, China, March 24, 2016 - German pharmaceutical giant Boehringer Ingelheim and Shanghai-based leading biopharma company Zai Lab today signed a supply agreement. Under the agreement, Boehringer Ingelheim will provide process optimization and manufacturing services for Zai Lab’s new monoclonal antibody. The new monoclonal antibody will be used to treat autoimmune diseases.

“Entering a supply agreement with Zai Lab is another key milestone for our biopharma business in China,” said Dr. Jiali Luo, general manager of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. “We believe with our advanced biopharma technology and quality management system, we will help Zai Lab facilitate its R&D and market launch of innovative bio-medicines for the treatment of autoimmune diseases.”

Boehringer Ingelheim China Biopharmaceutical Site, located in Zhangjiang, Shanghai, is company’s biologics manufacturing site in China, using mammalian cell culture technology for production. It’s also committed to becoming the leading biopharma contract manufacturing organization (CMO) in China. The biopharma CMO will turn the previous “manufacturing bottleneck” in the industry chain to a “service platform,” thus helping R&D-oriented companies commercialize their product pipelines and maximize the value.

“We are pleased with the collaboration with Boehringer Ingelheim. Their state-of-the-art bioprocessing expertise in the biopharmaceuticals field will accelerate the development of our innovative biologics programs.” said Dr. Samantha Du, founder and CEO of Zai Lab. “With the help of Boehringer Ingelheim’s world-class bioprocess capabilities and the pilot CMO program, we believe Zai Lab will step up efforts to bring innovative bio-medicines to the market and benefit patients quickly.”

“China’s State Food and Drug Administration has recently released a series of inspiring reform measures. Among them, the pilot program of Marketing Authorization Holder (MAH) will help spur R&D of new medicines and propel rapid growth of China’s pharmaceutical industry,” said David Preston, Chairman and CEO of Boehringer Ingelheim China, Hong Kong and Tai Wan. “As a global leader in biopharma contract manufacturing, Boehringer Ingelheim expects to tap the pilot biopharma CMO project in China to help Zai Lab and other research-driven enterprises accelerate clinical research and market launch of innovative medicines and benefit more patients in China.”


About Zai Lab

Zai Lab is a leading biopharmaceutical company based in China focused on discovering, developing and commercializing innovative medicines for unmet medical needs globally. The company is building a strong portfolio of therapeutic programs aimed at transforming patients’ lives. Zai Lab has a world class leadership team with deep experience at global pharmaceutical and biotech organizations. The team has a strong track record of success – successfully taken five novel drug candidates into clinical trials in China, pioneered new regulatory channels, secured regulatory approvals in record times, conducted multiple IND trials in the US, and brought the first China discovered drug into Global Phase III trials. Zai Lab is committed to build a globally leading drug research and development powerhouse with a culture of excellence and teamwork and a strong focus on fostering innovation and creativity. For more information, please visit www.zailaboratory.com


About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9% of its net sales. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its brand Boehringer Ingelheim BioXcellence™. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought more than 20 biopharmaceutical products to market.

Contact Us

Boehringer Ingelheim BioXcellence - Contact Us

Do you have any inquiries, questions or comments? Please get in touch with us.

What Shanghai can offer you

World map showing Shanghai

Boehringer Ingelheim Biopharmaceuticals in China (whitepaper)